These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 28933554)
1. Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin. Rink JS; Yang S; Cen O; Taxter T; McMahon KM; Misener S; Behdad A; Longnecker R; Gordon LI; Thaxton CS Mol Pharm; 2017 Nov; 14(11):4042-4051. PubMed ID: 28933554 [TBL] [Abstract][Full Text] [Related]
2. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620 [TBL] [Abstract][Full Text] [Related]
3. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. Dunleavy K; Erdmann T; Lenz G Cancer Treat Rev; 2018 Apr; 65():41-46. PubMed ID: 29549872 [TBL] [Abstract][Full Text] [Related]
4. Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis. Rink JS; Lin AY; McMahon KM; Calvert AE; Yang S; Taxter T; Moreira J; Chadburn A; Behdad A; Karmali R; Thaxton CS; Gordon LI J Biol Chem; 2021; 296():100100. PubMed ID: 33208460 [TBL] [Abstract][Full Text] [Related]
5. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251 [TBL] [Abstract][Full Text] [Related]
6. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Havranek O; Xu J; Köhrer S; Wang Z; Becker L; Comer JM; Henderson J; Ma W; Man Chun Ma J; Westin JR; Ghosh D; Shinners N; Sun L; Yi AF; Karri AR; Burger JA; Zal T; Davis RE Blood; 2017 Aug; 130(8):995-1006. PubMed ID: 28646116 [TBL] [Abstract][Full Text] [Related]
7. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Young RM; Wu T; Schmitz R; Dawood M; Xiao W; Phelan JD; Xu W; Menard L; Meffre E; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Staudt LM Proc Natl Acad Sci U S A; 2015 Nov; 112(44):13447-54. PubMed ID: 26483459 [TBL] [Abstract][Full Text] [Related]
8. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955 [TBL] [Abstract][Full Text] [Related]
9. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Chen L; Monti S; Juszczynski P; Daley J; Chen W; Witzig TE; Habermann TM; Kutok JL; Shipp MA Blood; 2008 Feb; 111(4):2230-7. PubMed ID: 18006696 [TBL] [Abstract][Full Text] [Related]
10. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343 [TBL] [Abstract][Full Text] [Related]
12. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955 [TBL] [Abstract][Full Text] [Related]
13. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma. Pore D; Bodo J; Danda A; Yan D; Phillips JG; Lindner D; Hill BT; Smith MR; Hsi ED; Gupta N Leukemia; 2015 Sep; 29(9):1857-67. PubMed ID: 25801911 [TBL] [Abstract][Full Text] [Related]
14. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169 [TBL] [Abstract][Full Text] [Related]
15. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway. Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124 [TBL] [Abstract][Full Text] [Related]
17. MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells. Jablonska E; Gorniak P; Szydlowski M; Sewastianik T; Bialopiotrowicz E; Polak A; Warzocha K; Juszczynski P Exp Hematol; 2017 Feb; 46():56-61.e1. PubMed ID: 27720936 [TBL] [Abstract][Full Text] [Related]
18. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system. Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967 [TBL] [Abstract][Full Text] [Related]
19. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343 [TBL] [Abstract][Full Text] [Related]